Progress and promise of pharmacodynamic biomarkers: novel strategies and assay considerations in drug development

Pharmacodynamic (PD) biomarkers provide crucial insights into a drug’s mechanism of action (MoA) and efficacy by measuring its effects on biological targets within an organism. PD biomarkers can be proximal (e.g. receptor occupancy, enzyme inhibition) or distal (e.g. downstream pathway modulation) to the biological target. In drug development, PD biomarkers are essential for monitoring patient response, assessing therapeutic efficacy, optimizing dosage strategies, and streamlining the drug development process by informing go/no-go decisions. In personalized medicine, PD biomarkers enable tailored treatments based on individual responses, enhancing both effectiveness and safety. Sound bioanalytical strategies and rigorous assay validation practices are key for successful integration of PD biomarkers into clinical trials. This paper outlines the bioanalytical and assay considerations for developing and validating informative PD biomarker assays and their use in drug development.

Article highlights

• Introduction

  • PD biomarkers validate mechanism of action (MoA) and target engagement, and inform on physiological effects.

  • They support dose optimization, accelerate decisions, and enhance trial efficiency.

• Preclinical Decision Framework

  • Assay development starts early, ideally after target validation, and evolves throughout the clinical program.

  • Lifecycle includes discovery, development, validation, and implementation aligned with context of use (COU) and transitions to clinical development.

• Early Drug Response Monitoring

  • PD biomarkers help characterize onset, magnitude, and duration of drug effects, and guide dose and schedule optimization.

  • Case studies illustrate successful use early clinical development to optimize dosing for confirmatory trials.

• Assay Development, Optimization & Validation

  • Platform Selection: Based on COU, biomarker properties, and assay requirements.

  • Method Optimization: Uses reference materials and statistical design (e.g., DoE) to refine conditions.

  • Solutions for bioanalytical challenges include technological innovation, robust validation, and strategic planning.

  • Validation assesses parameters such as accuracy, precision, sensitivity, specificity, dynamic range, stability and for some technologies, parallelism.

  • Fit-for-Purpose (FFP): Validation rigor matches the biomarker’s COU.

• Integration into Clinical Trials

  • Begin biomarker planning in preclinical phase using COU/FFP principles.

  • Use multimodal approaches and adaptive designs to link biomarkers with outcomes.

  • Leverage emerging technologies for deeper insights.

• Recent Advances, Emerging Trends and Alternative Approaches

  • AI enables mining of clinical datasets for biomarker discovery.

  • Liquid biopsies offer accessible alternatives to tissue biopsies.

  • Advanced platforms and approaches (e.g., high-dimensional flow cytometry, mass cytometry (CyTOF), high multiplex assays and imaging, multi-omics, spatial transcriptomics, mass spectrometry imaging and thermal shift assays) can enhance biomarker assessment.

• Conclusion

  • PD biomarkers are essential tools for understanding drug effects and guiding development.

  • Success depends on robust assay design, validation, and implementation into clinical strategy.

  • Technological progress continues to expand biomarker applications